{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T23:11:28Z","timestamp":1648681888241},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00393-014-1398-8","type":"journal-article","created":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T10:09:31Z","timestamp":1417774171000},"page":"907-916","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evidenz der Therapie chronisch-entz\u00fcndlicher Erkrankungen in Kindheit und Adoleszenz mit Biologika"],"prefix":"10.1007","volume":"73","author":[{"given":"H.-I.","family":"Huppertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.W.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,7]]},"reference":[{"key":"1398_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/11588140-000000000-00000","volume":"13","author":"Beresford","year":"2011","unstructured":"Beresford MW (2011) Juvenile idiopathic arthritis. Paediatr Drugs 13:161\u2013173","journal-title":"Paediatr Drugs"},{"key":"1398_CR2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","volume":"64","author":"Beukelman","year":"2012","unstructured":"Beukelman T, Haynes K, Curtis JR et al (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:1263\u20131271","journal-title":"Arthritis Rheum"},{"key":"1398_CR3","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"De","year":"2012","unstructured":"De Benedetti F, Brunner H, Nicola R et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385\u20132395","journal-title":"N Engl J Med"},{"key":"1398_CR4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11926-010-0090-5","volume":"12","author":"Cooper","year":"2010","unstructured":"Cooper N, Bussel JB (2010) The long-term impact of Rituximab for childhood immune thrombocytopenia. Curr Rheumatol Rep 12:94\u2013100","journal-title":"Curr Rheumatol Rep"},{"key":"1398_CR5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","volume":"62","author":"Diak","year":"2010","unstructured":"Diak P, Siegel J, LaGrenade L et al (2010) Tumor necrosis factor \u03b1 blockers and malignancy in children. Arthritis Rheum 62:2517\u20132524","journal-title":"Arthritis Rheum"},{"key":"1398_CR6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","volume":"4","author":"Dignass","year":"2010","unstructured":"Dignass A, Van Assche G, Lindsay JO et al (2010) The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current management. J Crohns Colitis 4:28\u201362","journal-title":"J Crohns Colitis"},{"key":"1398_CR7","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.0b013e3181f11daf","volume":"75","author":"Ghezzi","year":"2010","unstructured":"Ghezzi A, Pozzilli C, Grimaldi LM et al (2010) Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 75:912\u2013917","journal-title":"Neurology"},{"key":"1398_CR8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2011.581","volume":"69","author":"Gorman","year":"2012","unstructured":"Gorman MP, Tillema JM, Ciliax AM et al (2012) Daclizumab use in patients with pediatric multiple sclerosis. Arch Neurol 69:78\u201381","journal-title":"Arch Neurol"},{"key":"1398_CR9","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00296-011-2249-4","volume":"32","author":"Hedrich","year":"2012","unstructured":"Hedrich CM, Bruck N, Fiebig B et al (2012) Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis. Rheumatol Int 32:3525\u20133530","journal-title":"Rheumatol Int"},{"key":"1398_CR10","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1055\/s-2008-1027796","volume":"46","author":"Hoffmann","year":"2008","unstructured":"Hoffmann JC, Prei\u00df JC, Autschbach F et al (2008) S3-Leitlinie \u201eDiagnostik und Therapie des Morbus Crohn\u201c. Z Gastroenterol 46:1094\u20131146","journal-title":"Z Gastroenterol"},{"key":"1398_CR11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"Horneff","year":"2009","unstructured":"Horneff G, DeBock F, Foeldvari I et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis 68:519\u2013525","journal-title":"Ann Rheum Dis"},{"key":"1398_CR12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S et al (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. REACH Study Group. Gastroenterology 132(3):863\u2013873","journal-title":"Gastroenterology"},{"key":"1398_CR13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","volume":"143","author":"Hyams","year":"2012","unstructured":"Hyams JS, Griffiths A, Markowitz J et al (2012) Safety and efficacy of adalimumab for moderate to severe Crohn\u2019s disease in children. Gastroenterology 143:365\u2013374","journal-title":"Gastroenterology"},{"key":"1398_CR14","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","volume":"70","author":"Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner JB, Hachulla E, Cartwright R et al (2011) Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70:2095\u20132102","journal-title":"Ann Rheum Dis"},{"key":"1398_CR15","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"Lachmann","year":"2009","unstructured":"Lachmann HJ, Kon\u00e9-Paut I, Kuemmerle-Deschner JB et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360:2416\u20132425","journal-title":"N Engl J Med"},{"key":"1398_CR16","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"Lapeyraque","year":"2011","unstructured":"Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al (2011) Eculizumab in severe Shiga-toxin associated HUS. N Engl J Med 364:2561\u20132563","journal-title":"N Engl J Med"},{"key":"1398_CR17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763\u2013769","journal-title":"N Engl J Med"},{"key":"1398_CR18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810\u2013820","journal-title":"N Engl J Med"},{"key":"1398_CR19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ et al (2011) Efficacy of intravitreal Bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"1398_CR20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FHM et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum 63:545\u2013555","journal-title":"Arthritis Rheum"},{"key":"1398_CR21","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/art.34349","volume":"64","author":"Onel","year":"2012","unstructured":"Onel KB, Onel K (2012) Tumor necrosis factor inhibitors and cancer in juvenile idiopathic arthritis: disentangling the web. Arthritis Rheum 64:966\u2013969","journal-title":"Arthritis Rheum"},{"key":"1398_CR22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","volume":"358","author":"Paller","year":"2008","unstructured":"Paller AS, Siegfried EC, Langley RG et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358:241\u2013251","journal-title":"N Engl J Med"},{"key":"1398_CR23","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1600-6143.2010.03266.x","volume":"10","author":"Pape","year":"2010","unstructured":"Pape L, Offner G, Kreuzer M et al (2010) De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 10:2349\u20132354","journal-title":"Am J Transplant"},{"key":"1398_CR24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R et al (2011) A multicenter, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptos antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 70:747\u2013754","journal-title":"Ann Rheum Dis"},{"key":"1398_CR25","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096\u20133106","journal-title":"Arthritis Rheum"},{"key":"1398_CR26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. Lancet 372:383\u2013391","journal-title":"Lancet"},{"key":"1398_CR27","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P et al (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2396\u20132406","journal-title":"N Engl J Med"},{"key":"1398_CR28","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","volume":"64","author":"Sibley","year":"2012","unstructured":"Sibley CH, Plass N, Snow J et al (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64:2375\u20132386","journal-title":"Arthritis Rheum"},{"key":"1398_CR29","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.27741","volume":"62","author":"Simard","year":"2010","unstructured":"Simard JF, Neovius M, Hagelberg S et al (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 62:3776\u20133782","journal-title":"Arthritis Rheum"},{"key":"1398_CR30","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M et al (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998\u20131006","journal-title":"Lancet"},{"key":"1398_CR31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","volume":"91","author":"Biester","year":"2007","unstructured":"Biester S, Deuter C, Michels H et al (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91:319\u2013324","journal-title":"Br J Ophthalmol"},{"key":"1398_CR32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10067-009-1279-8","volume":"29","author":"Bilginer","year":"2010","unstructured":"Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Beh\u00e7et\u2019s disease. Clin Rheumatol 29:209\u2013210","journal-title":"Clin Rheumatol"},{"key":"1398_CR33","doi-asserted-by":"crossref","unstructured":"Brunner HI, Ruperto N, Zuber Z et al (2014) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis May 16 (Epub). DOI 10.1136\/annrheumdis-2014-205351","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"1398_CR34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.autrev.2011.11.025","volume":"11","author":"Comarmond","year":"2012","unstructured":"Comarmond C, Plaisier E, Dahan K et al (2012) Anti TNF-\u03b1 in refractory Takayasu\u2019s arteritis: cases series and review of the literature. Autoimmun Rev 11:678\u2013684","journal-title":"Autoimmun Rev"},{"key":"1398_CR35","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/rheumatology\/keq136","volume":"49","author":"Dallocchio","year":"2010","unstructured":"Dallocchio A, Canioni D, Ruemmele F et al (2010) Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology 49:1694\u20131698","journal-title":"Rheumatology"},{"key":"1398_CR36","unstructured":"European Medicines Agency. http:\/\/www.ema.europa.eu\/. Zugegriffen 11.11.2014"},{"key":"1398_CR37","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/art.23475","volume":"56","author":"Gattorno","year":"2008","unstructured":"Gattorno M, Pelagati MA, Meini A et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 56:1516\u20131520","journal-title":"Arthritis Rheum"},{"key":"1398_CR38","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasiglie D et al (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58:1505\u20131515","journal-title":"Arthritis Rheum"},{"key":"1398_CR39","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1002\/art.27682","volume":"62","author":"Giannini","year":"2010","unstructured":"Giannini EH, Ilowite NT, Lovell DJ et al (2010) Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 62:3259\u20133264","journal-title":"Arthritis Rheum"},{"key":"1398_CR40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/art.23620","volume":"58","author":"Goldbach-Mansky","year":"2008","unstructured":"Goldbach-Mansky R, Plass N, Chapelle D, NOMID study group (2008) Treatment of neonatal-onset multisystem inflammatory disease (NOMID\/CINCA) with IL-1 blocker anakinra, after 3 years on treatment. Arthritis Rheum 58:633","journal-title":"Arthritis Rheum"},{"key":"1398_CR41","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1002\/art.38596","volume":"66","author":"Hasija","year":"2014","unstructured":"Hasija RP, Silverman ED, Cho S et al (2014) A170: neoplasms in pediatric patients with rheumatic diseases exposed to biologics \u2013 a quarternary center\u2019s experience. Arthritis Rheumatol 66:S220\u2013S221","journal-title":"Arthritis Rheumatol"},{"key":"1398_CR42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/CE.S5992","volume":"4","author":"Herlin","year":"2009","unstructured":"Herlin T (2009) Tocilizumab: the evidence for its place in the treatment of juvenile idiopathic arthritis. Core Evid 4:181\u2013189","journal-title":"Core Evid"},{"key":"1398_CR43","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","volume":"34","author":"Hoffman","year":"2012","unstructured":"Hoffman HM, Throne ML, Amar NJ et al (2012) Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 34:2091\u20132103","journal-title":"Clin Ther"},{"key":"1398_CR44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1546-0096-11-35","volume":"11","author":"Hooper","year":"2013","unstructured":"Hooper M, Wenkert D, Bitman B et al (2013) Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports. Pediatr Rheumatol Online J 11:35","journal-title":"Pediatr Rheumatol Online J"},{"key":"1398_CR45","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/rheumatology\/kep122","volume":"48","author":"Horneff","year":"2009","unstructured":"Horneff G, Ebert A, Fitter S et al (2009) Safety and efficacy of once weekly etanercept 0.8\u00a0mg\/kg in a multicenter 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology 48:916\u2013919","journal-title":"Rheumatology"},{"key":"1398_CR46","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","volume":"73","author":"Horneff","year":"2014","unstructured":"Horneff G, Burgos-Vargas R, Constantin T et al (2014) Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 of the Clipper study. Ann Rheum Dis 73:1114\u20131122","journal-title":"Ann Rheum Dis"},{"key":"1398_CR47","unstructured":"Horneff G, Minden K, Huppertz HI (2013) Use of biologics in patients with juvenile idiopathic arthritis. Abstract EULAR, Madrid OP0157"},{"key":"1398_CR48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/art.38439","volume":"66","author":"Hui-Yuen","year":"2014","unstructured":"Hui-Yuen JS, Bermudez-Santiago LM, Isgro J et al (2014) A23: favorable response to belimumab in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 66(Suppl 11):37","journal-title":"Arthritis Rheumatol"},{"key":"1398_CR49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","volume":"10","author":"Hyams","year":"2012","unstructured":"Hyams J, Damaraju L, Blank M (2012) Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 10(4):391\u2013399","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1398_CR50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","volume":"28","author":"Ilowite","year":"2009","unstructured":"Ilowite N, Porras O, Reiff A et al (2009) Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 28(2):129\u2013137","journal-title":"Clin Rheumatol"},{"key":"1398_CR51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10067-010-1630-0","volume":"30","author":"Jansson","year":"2011","unstructured":"Jansson AF, Sengler C, Kuemmerle-Deschner J et al (2011) B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 30:87\u201397","journal-title":"Clin Rheumatol"},{"key":"1398_CR52","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00431-008-0685-2","volume":"167","author":"Jesus","year":"2008","unstructured":"Jesus AA, Oliveira JB, Aksentijevich I et al (2008) TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept. Eur J Pediatr 167(12):1421\u20131425","journal-title":"Eur J Pediatr"},{"key":"1398_CR53","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archdermatol.2011.49","volume":"147","author":"Kim","year":"2011","unstructured":"Kim NN, Lio PA, Morgan GA et al (2011) Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch Dermatol 147(7):831\u2013835","journal-title":"Arch Dermatol"},{"key":"1398_CR54","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/acr.22112","volume":"66","author":"Klotsche","year":"2014","unstructured":"Klotsche J, Minden K, Thon A et al (2014) Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept. Arthritis Care Res 66:253\u2013262","journal-title":"Arthritis Care Res"},{"key":"1398_CR55","doi-asserted-by":"crossref","first-page":"R202","DOI":"10.1186\/ar3535","volume":"13","author":"Kon\u00e9-Paut","year":"2011","unstructured":"Kon\u00e9-Paut I, Lachmann HJ, Kuemmerle-Deschner JB et al (2011) Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 13(6):R202","journal-title":"Arthritis Res Ther"},{"key":"1398_CR56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1651-2227.2010.01974.x","volume":"100","author":"Korppi","year":"2011","unstructured":"Korppi M, Gijn ME van, Antila K (2011) Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report. Acta Paediatr 100:21\u201325","journal-title":"Acta Paediatr"},{"key":"1398_CR57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1546-0096-12-3","volume":"12","author":"Lehman","year":"2014","unstructured":"Lehman TJ, Singh C, Ramanathan A et al (2014) Prolonges improvemebr of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 12(1):3","journal-title":"Pediatr Rheumatol Online J"},{"key":"1398_CR58","unstructured":"Lepore D, Quinn GE, Molle F et al (2014) Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology Jul 4 (Epub). DOI 10.1016\/j.ophtha2014.05.015"},{"key":"1398_CR59","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"Lovell","year":"2013","unstructured":"Lovell DJ, Giannini EH, Reiff AO et al (2013) Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 65:2486\u20132496","journal-title":"Arthritis Rheum"},{"key":"1398_CR60","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496\u20131504","journal-title":"Arthritis Rheum"},{"key":"1398_CR61","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1002\/art.38468","volume":"66","author":"Lovell","year":"2014","unstructured":"Lovell DJ, Ruperto N, Jarosova K et al (2014) A52: the impact of adalimumab on growth in patients with juvenile idiopathic arthritis. Arthritis Rheum 66:S77\u2013S78","journal-title":"Arthritis Rheum"},{"key":"1398_CR62","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0883073810381445","volume":"26","author":"Mahmood","year":"2011","unstructured":"Mahmood NA, Silver K, Onel K et al (2011) Efficacy and safety of rituximab in pediatric neuromyelitis optica. J Child Neurol 26:244\u2013247","journal-title":"J Child Neurol"},{"key":"1398_CR63","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1358\/dot.2009.45.6.1378935","volume":"45","author":"McDermott","year":"2009","unstructured":"McDermott MF (2009) Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today 45:423\u2013430","journal-title":"Drugs Today"},{"key":"1398_CR64","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1111\/aos.12339","volume":"92","author":"Moran","year":"2014","unstructured":"Moran S, O\u2019Keefe M, Hartnett C et al (2014) Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity. Acta Ophthalmol 92(6):e496\u2013497","journal-title":"Acta Ophthalmol"},{"key":"1398_CR65","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3748\/wjg.v18.i11.1229","volume":"18","author":"Nattiv","year":"2012","unstructured":"Nattiv R, Wojcicki JM, Garnett EA et al (2012) High-dose infliximab for treatment of pediatric ulcerative colitis: a survey of clinical practice. World J Gastroenterol 18(11):1229\u20131234","journal-title":"World J Gastroenterol"},{"key":"1398_CR66","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4321\/S1130-01082013001000002","volume":"105","author":"Navas","year":"2013","unstructured":"Navas L\u00f3pez VM, Blasco-Alonso J, Gir\u00f3n-Fern\u00e1ndez-Crehuet F et al (2013) Efficacy and safety of adalimumab in the treatment of Crohn\u2019s disease in children. Rev Esp Enferm Dig 105(10):579\u2013584","journal-title":"Rev Esp Enferm Dig"},{"key":"1398_CR67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/art.38435","volume":"66","author":"Olfat","year":"2014","unstructured":"Olfat M, Silverman ED, Levy DM (2014) Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood onset systemic lupus erythematosus. Arthritis Rheumatol 66(Suppl 11):30","journal-title":"Arthritis Rheumatol"},{"key":"1398_CR68","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2011.1671","volume":"306","author":"Otten","year":"2011","unstructured":"Otten MH, Prince FHM, Armbrust W et al (2011) Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 306:2340\u20132347","journal-title":"JAMA"},{"key":"1398_CR69","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2012-201991","volume":"72","author":"Otten","year":"2013","unstructured":"Otten MH, Anink J, Spronk S et al (2013) Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisins. Ann Rheum Dis 72:1806\u20131812","journal-title":"Ann Rheum Dis"},{"key":"1398_CR70","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3899\/jrheum.090150","volume":"36","author":"Park","year":"2009","unstructured":"Park JH, Seo GY, Lee JS et al (2009) Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 36:2158\u20132163","journal-title":"J Rheumatol"},{"key":"1398_CR71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12016-011-8262-2","volume":"42","author":"Pontikaki","year":"2012","unstructured":"Pontikaki I, Shahi E, Frasin LA et al (2012) Skin manifestations induced by TNF-\u03b1 inhibitors in juvenile idiopathic arthritis. Clin Rev Allergy Immunol 42:131\u2013134","journal-title":"Clin Rev Allergy Immunol"},{"key":"1398_CR72","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/rheumatology\/keq432","volume":"50","author":"Prince","year":"2011","unstructured":"Prince FHM, DeBekker-Grob EW, Twilt M et al (2011) An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch arthritis and biologicals in children register. Rheumatology 50:1131\u20131136","journal-title":"Rheumatology"},{"key":"1398_CR73","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","volume":"69","author":"Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Cuttica R et al (2010) Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label extension. Ann Rheum Dis 69:718\u2013722","journal-title":"Ann Rheum Dis"},{"key":"1398_CR74","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","volume":"62","author":"Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792\u20131802","journal-title":"Arthritis Rheum"},{"key":"1398_CR75","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"Ruperto","year":"2012","unstructured":"Ruperto N, Quartier P, Wulffraat N et al (2012) A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 64:557\u2013567","journal-title":"Arthritis Rheum"},{"key":"1398_CR76","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/acr.22198","volume":"66","author":"Rouster-Stevens","year":"2014","unstructured":"Rouster-Stevens KA, Ferguson L, Morgan G et al (2014) Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res 66(5):783\u2013787","journal-title":"Arthritis Care Res"},{"key":"1398_CR77","first-page":"1502","volume":"63","author":"Schmidt","year":"2011","unstructured":"Schmidt J, Kermani TA, Bacani AK et al (2011) Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term follow-up. Arthritis Rheum 63(Suppl 10):1502","journal-title":"Arthritis Rheum"},{"key":"1398_CR78","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ajo.2009.06.003","volume":"148","author":"Sen","year":"2009","unstructured":"Sen HN, Levy-Clarke G, Faia LJ et al (2009) High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 148:696\u2013703","journal-title":"Am J Ophthalmol"},{"key":"1398_CR79","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.20404","volume":"63","author":"Simonini","year":"2011","unstructured":"Simonini G, Taddio A, Cattalini M et al (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 63:612\u2013618","journal-title":"Arthritis Care Res"},{"key":"1398_CR80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1546-0096-12-13","volume":"12","author":"Stoll","year":"2014","unstructured":"Stoll ML, Cron RQ (2014) Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J 12:13","journal-title":"Pediatr Rheumatol Online J"},{"key":"1398_CR81","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/cid\/cit489","volume":"57","author":"Toussi","year":"2013","unstructured":"Toussi SS, Pan N, Walters HM et al (2013) Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-\u03b1 inhibitors: systematic review of the literature. Clin Infect Dis 57:1318\u20131330","journal-title":"Clin Infect Dis"},{"key":"1398_CR82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/acr.20337","volume":"63","author":"Ungar","year":"2011","unstructured":"Ungar WJ, Costa V, Hancock-Howard R et al (2011) Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res 63:111\u2013119","journal-title":"Arthritis Care Res"},{"key":"1398_CR83","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/art.30314","volume":"63","author":"Unizony","year":"2011","unstructured":"Unizony S, Arias-Urdaneta L, Miloslavsky E et al (2011) Tocilizumab for the treatment of large vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyaldia rheumatic: a case series. Arthritis Rheum 63(Suppl 10):1507","journal-title":"Arthritis Rheum"},{"key":"1398_CR84","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3899\/jrheum.100809","volume":"38","author":"VanDijken","year":"2011","unstructured":"VanDijken TD, Vastert SJ, Gerloni VM et al (2011) Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 38:1441\u20131446","journal-title":"J Rheumatol"},{"key":"1398_CR85","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ et al (2012) Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 64(6):2012\u20132021","journal-title":"Arthritis Rheum"},{"key":"1398_CR86","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","volume":"41","author":"Wendling","year":"2011","unstructured":"Wendling D, Paccou J, Berthelot JM et al (2011) New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 41:503\u2013510","journal-title":"Semin Arthritis Rheum"},{"key":"1398_CR87","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"Yoursy","year":"2006","unstructured":"Yoursy TA, Major EO, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924\u2013933","journal-title":"N Engl J Med"},{"key":"1398_CR88","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","volume":"62","author":"Zulian","year":"2010","unstructured":"Zulian F, Balzarin M, Falcini F et al (2010) Abatacept for severe anti-tumor necrosis factor \u03b1 refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 62:821\u2013825","journal-title":"Arthritis Care Res"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-014-1398-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-014-1398-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-014-1398-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:36:19Z","timestamp":1559061379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-014-1398-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1007\/s00393-014-1398-8","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}